Depakote ER Promotion Cannot Claim Bioequivalence With Original Drug – FDA
Executive Summary
FDA is discouraging Abbott from comparing its extended-release and delayed-release versions of its manic depression treatment Depakote in promotional materials, a move that undercuts the central tenet of most industry ever-greening strategies